Panion & Bf Biotech Inc. (1760.TW)
TWD 68.7
(-2.41%)
TWD 68.7
(-2.41%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.32 Billion TWD | 21.88% |
| 2022 | 1.08 Billion TWD | 6.5% |
| 2021 | 1.02 Billion TWD | -44.38% |
| 2020 | 1.83 Billion TWD | 231.68% |
| 2019 | 552.94 Million TWD | 14.15% |
| 2018 | 484.38 Million TWD | 17.53% |
| 2017 | 412.15 Million TWD | 7.1% |
| 2016 | 384.81 Million TWD | -3.87% |
| 2015 | 400.32 Million TWD | 0.8% |
| 2014 | 397.15 Million TWD | 15.46% |
| 2013 | 343.98 Million TWD | -46.7% |
| 2012 | 645.34 Million TWD | 1.29% |
| 2011 | 637.1 Million TWD | 13.75% |
| 2010 | 560.09 Million TWD | 2.05% |
| 2009 | 548.82 Million TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.39 Billion TWD | 3.93% |
| 2024 Q1 | 1.34 Billion TWD | 1.56% |
| 2023 FY | 1.32 Billion TWD | 21.88% |
| 2023 Q4 | 1.32 Billion TWD | 11.23% |
| 2023 Q1 | 1.19 Billion TWD | 9.69% |
| 2023 Q3 | 1.19 Billion TWD | -13.25% |
| 2023 Q2 | 1.37 Billion TWD | 15.15% |
| 2022 Q2 | 1.16 Billion TWD | 4.38% |
| 2022 Q4 | 1.08 Billion TWD | -5.55% |
| 2022 Q1 | 1.11 Billion TWD | 9.68% |
| 2022 FY | 1.08 Billion TWD | 6.5% |
| 2022 Q3 | 1.15 Billion TWD | -1.51% |
| 2021 Q2 | 1.72 Billion TWD | -9.43% |
| 2021 Q3 | 1.07 Billion TWD | -37.68% |
| 2021 Q4 | 1.02 Billion TWD | -5.37% |
| 2021 FY | 1.02 Billion TWD | -44.38% |
| 2021 Q1 | 1.9 Billion TWD | 4.14% |
| 2020 Q3 | 688.55 Million TWD | -5.11% |
| 2020 Q2 | 725.65 Million TWD | 4.91% |
| 2020 Q1 | 691.7 Million TWD | 25.1% |
| 2020 Q4 | 1.83 Billion TWD | 166.35% |
| 2020 FY | 1.83 Billion TWD | 231.68% |
| 2019 Q2 | 597.2 Million TWD | 15.22% |
| 2019 FY | 552.94 Million TWD | 14.15% |
| 2019 Q3 | 444.56 Million TWD | -25.56% |
| 2019 Q4 | 552.94 Million TWD | 24.38% |
| 2019 Q1 | 518.33 Million TWD | 7.01% |
| 2018 Q3 | 444.9 Million TWD | -14.6% |
| 2018 FY | 484.38 Million TWD | 17.53% |
| 2018 Q4 | 484.38 Million TWD | 8.87% |
| 2018 Q2 | 520.94 Million TWD | 43.81% |
| 2018 Q1 | 362.24 Million TWD | -12.11% |
| 2017 Q4 | 412.15 Million TWD | 4.14% |
| 2017 FY | 412.15 Million TWD | 7.1% |
| 2017 Q3 | 395.75 Million TWD | -7.4% |
| 2017 Q2 | 427.37 Million TWD | 0.0% |
| 2017 Q1 | - TWD | -100.0% |
| 2016 Q1 | 292.81 Million TWD | -26.86% |
| 2016 Q2 | 361 Million TWD | 23.29% |
| 2016 Q4 | 384.81 Million TWD | 0.0% |
| 2016 FY | 384.81 Million TWD | -3.87% |
| 2015 Q1 | 329.39 Million TWD | -17.06% |
| 2015 FY | 400.32 Million TWD | 0.8% |
| 2015 Q2 | 434.93 Million TWD | 32.04% |
| 2015 Q4 | 400.32 Million TWD | 26.86% |
| 2015 Q3 | 315.56 Million TWD | -27.45% |
| 2014 Q1 | 270.9 Million TWD | -21.24% |
| 2014 Q2 | 357.14 Million TWD | 31.83% |
| 2014 FY | 397.15 Million TWD | 15.46% |
| 2014 Q4 | 397.15 Million TWD | 29.75% |
| 2014 Q3 | 306.07 Million TWD | -14.3% |
| 2013 Q1 | 673.79 Million TWD | 4.41% |
| 2013 Q2 | 673.79 Million TWD | 0.0% |
| 2013 Q3 | 257.74 Million TWD | -61.75% |
| 2013 Q4 | 343.98 Million TWD | 33.46% |
| 2013 FY | 343.98 Million TWD | -46.7% |
| 2012 Q2 | 639.71 Million TWD | 0.0% |
| 2012 Q3 | 657 Million TWD | 2.7% |
| 2012 FY | 645.34 Million TWD | 1.29% |
| 2012 Q4 | 645.34 Million TWD | -1.77% |
| 2011 Q2 | 599.46 Million TWD | 0.0% |
| 2011 FY | 637.1 Million TWD | 13.75% |
| 2011 Q4 | 637.1 Million TWD | 0.0% |
| 2010 Q4 | 560.09 Million TWD | 0.0% |
| 2010 FY | 560.09 Million TWD | 2.05% |
| 2009 FY | 548.82 Million TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Apex Biotechnology Corp. | 500.07 Million TWD | -164.783% |
| Sinphar Pharmaceutical Co.,Ltd. | 2.85 Billion TWD | 53.593% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 1.82 Billion TWD | 27.304% |
| GenMont Biotech Incorporation | 204.05 Million TWD | -548.881% |
| Abnova (Taiwan) Corporation | 69.42 Million TWD | -1807.267% |
| Adimmune Corporation | 3.7 Billion TWD | 64.28% |
| Tanvex BioPharma, Inc. | 1.94 Billion TWD | 31.828% |
| Polaris Group | 1.46 Billion TWD | 9.604% |
| Energenesis Biomedical CO.,LTD. | 24.58 Million TWD | -5285.37% |
| UnicoCell Biomed Co., Ltd. | 89.48 Million TWD | -1379.657% |
| PELL Bio-Med Technology Co. Ltd. | 236.76 Million TWD | -459.247% |